QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, ... more
QIAGEN joins CANCER-ID consortium for liquid biopsy workflows
Public-private partnership aims to standardize and clinically validate blood-based biomarkers
QIAGEN N.V. announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.
Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through the identification of circulating tumor cells and tumor-related nucleic acids in blood samples, have highlighted the need for standardized methods and workflows to avoid unreliable or even false analytical test results, including sequencing bias. The CANCER-ID consortium of 36 partners from 13 countries is a project of Europe’s Innovative Medicines Initiative (IMI) and will conduct clinical trials using liquid biopsy methods as part of its efforts to accelerate the development of better and safer medicines for patients.
“QIAGEN is pleased to be joining CANCER-ID to help develop standards and conduct clinical validation to enable broad adoption of reliable molecular analyses from liquid biopsies. Personalized healthcare is providing life-saving genomic insights, and blood-based biomarkers offer the potential to transform diagnosis and patient monitoring due to significantly easier access,” said Markus Sprenger-Haussels, Senior Director and Head of Sample Technologies in the Life Sciences Business Area.
“Creating standardized methods for liquid biopsies, as well as standards for Sample to Insight workflows, is key to enabling routine with the highest quality samples, up-front processing and links to analytical tests that are critical for achieving actionable insights. As a pioneer in developing liquid biopsy sample technologies, we look forward to sharing QIAGEN’s experience with our colleagues in CANCER-ID and contributing a wide range of solutions that can help to improve outcomes for cancer patients.”
The consortium’s scientific coordinator, Prof. Dr. Klaus Pantel, Director of the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf in Germany, stated: “We welcome the participation of QIAGEN, which has a long track record in setting standards in sample processing and in molecular testing solutions. CANCER-ID is an excellent example of a public-private partnership enabling a collaborative research approach to come up with novel concepts in modern cancer therapy. The consortium brings together a large, experienced team of experts from academic and clinical research, innovative small- to medium-sized enterprises, diagnostics and pharmaceutical companies, far beyond the scope of traditional ‘one-on-one’ industry-academia collaborations.”
Liquid biopsies hold promise for use in a range of clinical applications, including disease screening in patients for whom surgical biopsy is inappropriate, or in repeated testing to monitor changes in disease status. However, protocols for implementation of liquid biopsies are currently very varied, and the collection of blood-based biomarkers has not yet been standardized. These areas need to be addressed since differences in sample processing techniques can result in material changes of nucleic acid profiles and cause genomic bias in subsequent sequencing. CANCER-ID intends to develop standards for liquid biopsy workflows in breast and lung cancer to support downstream applications such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) analysis. The consortium also partners with clinical studies to validate the use of liquid biopsies to identify relevant cancer biomarkers.
- liquid biopsy
- tumor biology
- clinical studies
- cancer therapy
- cancer biomarkers
- circulating tumor cells
- clinical research
QIAGEN announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19. QIAGEN has historically allocated global production capaci ... more
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to ... more
- 1Virtual screening for active substances against the coronavirus
- 2analytica 2020 is postponed
- 3Thermo Fisher Scientific to Acquire QIAGEN
- 4Smartphone lab finds coronavirus in saliva
- 5The digital laboratory live and tangible
- 6Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization
- 7analytica 2020: Bioanalysis for personalized medicine
- 8Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus
- 9New membrane separates small organic molecules
- 10FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
- Is it time to abandon the Nobel Prize?
- Imperial and Tsinghua University launch seed fund for 'ambitious collaborations'
- Analytik Jena and BAM agree to cooperate in research
- Google provides open source library for quantum chemistry
- Adjustment of drug dose for rheumatoid arthritis by diagnostic method
- Pool testing of SARS-CoV-02 samples increases worldwide test capacities many times over
- Bosch develops rapid test for COVID-19
- Microflora of glasses: the mini universe on your nose
- A pigment from ancient Egypt to modern microscopy
- Unraveling the optical parameters: New method to optimize plasmon enhanced spectroscopy